Sequoia-backed Qure.ai gets USFDA nod for CT scan, first for Indian AI firm

American regulator's decision covers four critical abnormalities identified by Qure.ai's emergency room product namely intracranial bleeds, mass effect, midline shift, and cranial fractures

Sequoia-backed imaging Artificial Intelligence provider Qure.ai has received the US Food and Drug Administration’s clearance for its head CT scan product qER, becoming the first Indian AI company to receive the regulator's approval. 

The FDA's decision covers four critical abnormalities identified by Qure.ai’s emergency room product namely intracranial bleeds, mass effect, midline shift, and cranial fractures.

“Patient outcomes depend directly on the onset-to-treatment time, especially for brain injuries. Every day doctors are required to weigh the benefits of a potentially life-saving surgery versus the risks of an intracranial bleed or other complication. The sooner they have in-depth information that helps them make